Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Texas , Sept. 11, 2014 XBiotech ... high throughput filling machine that the Company says will ... The fully integrated system is designed to fill, stopper ... the manufacturing process. Additionally, the unit is said to ... scanning system to provide a high level of quality ...
(Date:9/11/2014)... 11, 2014 The Registration Committee ... is now open for Pittcon 2015, the world’s ... The event will be held March 8-12, 2015, ... Louisiana. , The discounted registration fee of ... after 2/20/2015). This affordable price includes unlimited week-long ...
(Date:9/11/2014)... Francisco, California (PRWEB) September 11, 2014 ... of software and IT systems that support clinical ... Annotation™ (GVA™) Service that now supports the interpretation ... resulting in a single, user-friendly report that contains ... been used toward cancer treatment planning and support ...
(Date:9/11/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... that it intends to conduct a Private Placement ... funding its preclinical development activities and financial commitments ... The Company is proposing to complete a ... shares at a price of US$0.10 per Share, ...
Breaking Biology Technology:Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 3Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4
... ... Sciences Division , ... Beijing, China (PRWEB) December 9, 2009 -- China-based CSOFT International Ltd., a leading provider ... for the global market, announced today the hiring of Tammy Werner as Director of ...
... release is available in Spanish . , ... and characterized for the first time different antioxidant compounds from ... herb called Teucrium polium. They have used two new techniques, ... them to identify and quantify a great part of the ...
... , CLEVELAND, Dec. 8 ... the market with a Smart Green(TM) focus. ... packaging, Nutek,s products continue to provide safe alternatives ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) , (Logo: ...
Cached Biology Technology:CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3New antioxidant compounds have been identified in foods such as olive oil, honey and nuts 2Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:9/12/2014)... data storage and processing from the user,s computer on ... storage space and computing power that they can then ... to connect to a single desktop or other computer ... concerns about the increased energy demands of sustaining distributed ... an individual user,s laptop might be shut down when ...
(Date:9/12/2014)... of dendritic cells in human skin have assorted functions ... report researchers in the journal EMBO Molecular Medicine ... the composition of dendritic cells in psoriatic skin lesions ... the disease. , "We urgently need new ways ... to patients and reduce the incidence of known side ...
(Date:9/11/2014)... had a Wisconsin zip code if the originally proposed ... a straight line from the southernmost tip of Lake ... River confluence. University of Illinois soil scientist Ken Olson ... changed, the state of Illinois would have a much ... of the Illinois Territory ceded to Wisconsin when it ...
Breaking Biology News(10 mins):Cutting the cloud computing carbon cost 2Dendritic cells affect onset and progress of psoriasis 2Original northern border of Illinois was south of Chicago and Lake Michigan 2Original northern border of Illinois was south of Chicago and Lake Michigan 3
... and measures, Johns Hopkins researchers have shown that ... mystical/spiritual experiences descriptively identical to spontaneous ones people ... experiences apparently prompt positive changes in behavior and ... , The agent, a plant alkaloid called psilocybin, ...
... Researchers at Cold Spring Harbor Laboratory on Long Island have ... brain is the chief target of the widely prescribed antidepressant ... specific treatments for depression, with fewer side effects, to be ... studies of the factors that control how, when, and where ...
... first time that embryonic stem (ES) cells cultured in ... produce viable offspring. The research, published in the July ... future studies, including investigation of mechanisms involved in sperm ... , Previous studies have shown that ES cells grown ...
Cached Biology News:Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 2Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 3Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 4Prozac's target revealed 2Sperm created in the laboratory from embryonic stem cells produce viable progeny 2
...
... Molecular Probes is pleased to ... for the ultrasensitive detection of primary ... at Indiana University, the ATTO-TAG reagents ... o-phthaldialdehyde (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, ...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
... low freezers , Ultima II ... material storage, Ultima II represents the finest, ... general purpose and blood bank configurations, each ... microprocessor control system with built-in voltage boost ...
Biology Products: